Object: Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease with characterized by progressive fibrosis. Galectin-3(Gal-3) is a B-galactoside binding lectin plays a central role in inflammation and fibrosis. In our study, we aimed to define levels of serum galectin-3 protein in IPF patients by comparing them with healthy subjects. We also aimed to show that galectin-3 concentrations can be used as a diagnostic and prognostic biomarker in the serum of IPF patients and that the use of galectin-3 inhibitors in combination with antifibrotic treatments may be useful in the therapeutic management of fibrosis.
Methods: 44 patients with IPF and 35 control patients who were followed up in our outpatient clinic between 2016 and 2022 were evaluated, anamnesis, spirometric measurements and galectin-3 results were recorded. Patients were grouped according to their antifibrotic treatment.
Results: The mean galectin-3 level in the patient group was 8.4 ng/ml and in the control group was 8.2 ng/ml. Serum levels were 8.9 ng/ml in pirfenidone users and 8.2 ng/ml in nintedanib users. Gal-3 was found to be higher in patients taking pirfenidone compared to nintedanib, but there was no statistically significant difference (p>0.05).
Conclusion: Galectin-3 levels were found to be slightly higher in IPF patients compared to healthy subjects. In addition, gal-3 levels decreased as the follow-up period increased in IPF patients in our study. Considering that the patients were receiving pirfenidone or nintedanib treatment during the follow-up period, it may be possible that galectin-3 levels decreased as exposure to these drugs increased. Further studies are needed to clarify these mechanisms.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.rmed.2025.108028 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Acute Exacerbation of Idiopathic Pulmonary Fibrosis in the Setting of Acute Eosinophilic Pneumonia.
HCA Healthc J Med
February 2025
LewisGale Medical Center, Salem, Virginia.
Description Idiopathic pulmonary fibrosis (IPF) is a progressive disease characterized by gradual destruction and replacement of pulmonary parenchyma with fibrous tissue, which occurs in conjunction with chronic inflammation. It is often considered a prototypical interstitial lung disease and is both the most prevalent and perhaps the most dangerous in that family. Although the disease is uncommon in the general population, its prevalence increases with age and is typically diagnosed around the age of 65.
View Article and Find Full Text PDFIncidence, Prevalence, and Mortality of Interstitial Lung Diseases in Alberta, Canada: A Population-based Study.
Ann Am Thorac Soc
March 2025
University of Toronto, Medicine, Toronto, Ontario, Canada.
Background The epidemiology of adult interstitial lung disease (ILD) is uncertain, given heterogeneous estimates from prior studies. The objective of this study was to define the incidence, prevalence, and mortality of ILD over a 10-year period using population-based data. Methods We created an administrative ILD cohort in Alberta, Canada between 2010-2019 using population-based administrative data (inpatient, ambulatory, and outpatient physician billing databases) for a repeat cross-sectional study.
View Article and Find Full Text PDFNavigating interstitial lung disease associated with rheumatoid arthritis (RA-ILD): from genetics to clinical landscape.
Front Med (Lausanne)
February 2025
Respiratory Disease Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy.
Rheumatoid arthritis (RA) is a systemic autoimmune disease that affects millions of people worldwide and is characterized by persistent inflammation, pain, and joint destruction. In RA, the dysregulation of the immune system is well documented. However, the genetic basis of the disease is not fully understood, especially when extra-articular organs are involved.
View Article and Find Full Text PDFSafety, Tolerability, and Pharmacokinetics of SC1011 (Sufenidone), a Novel Antifibrotic Small Molecule, in Phase 1 Studies in Healthy Subjects.
Clin Transl Sci
March 2025
The First Affiliated Hospital of Guangzhou, University of Chinese Medicine, Guangzhou, Guangdong, China.
SC1011 (sufenidone) is a novel pyridone derivative with therapeutic potential for idiopathic pulmonary fibrosis (IPF). Two Phase 1 studies evaluated the safety and pharmacokinetics of single (SAD) and multiple ascending doses (MAD) of SC1011 immediate-release (IR) and modified-release (MR) oral formulations in healthy adult subjects. In Phase 1a, subjects were randomized to receive oral SC1011 IR or placebo in SAD (50 mg-300 mg) or MAD (100 mg and 200 mg) twice daily for 7 days.
View Article and Find Full Text PDFEpidemiology of idiopathic pulmonary fibrosis in central and Western Pennsylvania.
Respir Res
March 2025
Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease, University of Pittsburgh, Pittsburgh, PA, USA.
Background/rationale: Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive disease of unknown origin. Establishing the epidemiology of IPF has been challenging due to diagnostic complexity, poor survival, low prevalence, and heterogeneity of ascertainment methodologies.
Objectives: This research aimed to estimate the rates of IPF in central and western Pennsylvania and to pilot the use of capture recapture (CR) methods to estimate the disease incidence.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!